Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 study of oral GSK5460025 in dMMR/MSI-H solid tumors
jRCT2031250372Phase 2Recruiting
- Sponsor
- GSK
- Start
- Oct 2025
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of GSK5460025 in Nonhematologic neoplasms, colorectal cancer (CRC) and endometrial cancer (EC) (2 arms), sponsored by GSK. Primary endpoints: Number of participants with dose limiting toxicities (DLTs) per dose level, Number of participants with treatment emergent serious adverse events (TESAEs) and treatment emergent adverse events (TEAEs) by severity per dose level and 3 more. Started Oct 2025; status: recruiting.
02
Drugs
GSK5460025
03
Conditions
Nonhematologic neoplasmscolorectal cancer (CRC)endometrial cancer (EC)
Beyond the preview
Go deeper on jRCT2031250372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250372.